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OBJECTIVE
To examine time trends inmortality rates and causes of death in patients with type 1
diabetes and end-stage renal disease on dialysis and after kidney transplantation.
RESEARCH DESIGN AND METHODS
In a nationwide retrospective cohort analysis, all patients with type 1 diabetes in
Finlandwho received a kidney transplant alonewere comparedwith patientswho
remained on dialysis. The main outcome was patient survival after starting
dialysis. The cohort was divided into dialysis, functioning kidney transplant, and
dialysis after transplant loss. Causes of death were retrieved and standardized
mortality ratios calculated.
RESULTS
We studied 2,383 patients. Patients survived a median of 15.9 years after a
successful transplant, 11.2 years if transplant function was lost, and 2.9 years if they
remained on chronic dialysis. Standardized mortality ratio decreased in all sub-
groups during the past four decades: from 2005 onwards, it was 3.9 in patients
receiving a kidney transplant, 11.5 in patients with graft loss, and 32.5 in patients on
dialysis. The most common cause of death in all patients was ischemic heart disease
(45%) followed by infection (18%), which was more common in patients on dialysis.
CONCLUSIONS
Kidney transplantation is the treatment of choice for patients with type 1 diabetes
and end-stage renal disease because it substantially reduces the excess death risk
when compared with dialysis. Even when kidney graft function is lost, the excess
death risk is still considerably lower. Although overall mortality has decreased over
the years, premature death due to ischemic heart disease remains high.
Type 1 diabetes (T1D), a common disease in children and young adults, is associated
with high risk of both acute and chronic complications. Diabetic nephropathy is a
severe complication in patients with T1D, and in Finland, recent data show that 7.0%
of the patients progress to end-stage renal disease (ESRD) after 30 years of T1D (1),
whereas in the U.S., 25% have been shown to progress to ESRD after 40 years of T1D
(2). Moreover, registry data show that between 4 and 17% of patients starting renal
replacement treatment (RRT) have T1D (3,4). It is well known that patients with ESRD
carry a manifold increased risk of premature mortality when compared with the
general population, and this is particularly true for patients with T1D (5,6).
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Even though the treatment of choice
for patients with ESRD is kidney trans-
plantation (KT), earlier studies have
shown that the independence from di-
alysis has not reversed the excess mor-
tality observed in transplanted patients
(7). This is surprising given that during
the past four decades, there have been
remarkable improvements in not only
surgical techniques but also immuno-
suppressive medications. Although there
have been several improvements in
diabetes care, the mortality rates for
individuals with T1D after KT have re-
mained higher compared with subjects
without diabetes, and this constitutes a
major challenge for the health care sys-
tem due to multiple comorbidities in
this patient group (8). Of note, com-
bined kidney and pancreas transplanta-
tion provides better survival than KT
alone, particularly in the case of de-
ceased donors (9). Over the last three
decades, the number of pancreas
transplantations grew remarkably.
As of December 2014, .29,000 pan-
creas transplants in the U.S. and
19,000 outside the U.S. had been per-
formed. Also noteworthy is that during
the last decade, the rate of pancreas
transplantation has declined by 20%
in the U.S., probably due to a decline
in organ donor quality (10). Despite
the advances, KT recipients die prema-
turely most commonly due to cardiovas-
cular disease, infections, or malignancy
(11,12).
The incidence rate of T1D is increasing
at a rate of 3–5% per year (13), and this is
particularly true for Western countries.
Notably, Finland has the highest T1D
incidence rate in the world (14) and
access to nationwide comprehensive
registries, which provides a unique op-
portunity to study the factors affecting
patient survival in this patient group.
Our aim was therefore to examine the
time trends of mortality and cause of
death in a nationwide cohort study of pa-
tients with T1D after KT.
RESEARCH DESIGN AND METHODS
Study Population
The study population included all Finn-
ish patients with T1D who progressed to
ESRD and received a KT after initiation of
dialysis. Data were obtained from the
Finnish Kidney Transplant Registry cov-
ering the period from 1964 to November
2016. We excluded recipients of simul-
taneous pancreas and kidney transplants,
pancreas after kidney transplants, and
kidney retransplantations. The reason
for excluding pancreas transplantation
is that in Finland, there were only
78 such cases by November 2016.
Data for the D cohort (patients who
remained on dialysis) include data from
1975 onward that were drawn from
the Helsinki University Hospital District
database, which represents nearly one-
third of all patients on dialysis in
Finland. Vital status and causes of death
were obtained from the Finnish Cause of
Death Register, and death certiﬁcates
were reviewed in uncertain cases. Fur-
thermore, mortality data were veriﬁed
with the database of the Finnish Di-
abetic Nephropathy Study (FinnDiane),
which is a nationwide, ongoing multi-
center study with the aim of identifying
genetic and clinical risk factors for ne-
phropathy in T1D (15).
The variables procured from the data-
bases were date of initiation of dialysis,
age at start of dialysis, age at transplan-
tation, type and number of KTs, recipient
and donor sex, type of donor, donor age,
HLA mismatches, panel-reactive anti-
body titers, delayed graft function oc-
currence, acute rejection episodes, KT
loss date, patient’s death date, and cause
of death. We divided the cohort accord-
ing to the treatment modality: patients
who remained on dialysis (D), those
who received a kidney transplant but
returned to dialysis after losing graft
function (KT-D), and patients who
maintained kidney allograft function
(KT). The patients’ ﬂowchart is avail-
able in Supplementary Fig. 1. Causes
of death were retrieved initially as re-
corded in the death certiﬁcates and
further regrouped for era comparison.
The causes of death were regrouped
for comparison as follows: ischemic
heart disease (including fatal acute myo-
cardial infarction, heart insufﬁciency,
arrhythmia, and sudden death), fatal
stroke (including both hemorrhagic
and ischemic), peripheral vascular dis-
ease (PVD) (deﬁned as a complication
of atherosclerotic vessels of the limb
including amputation, gangrene, and
sepsis as a consequence of an infected
limb), infections (excluding those as a
consequence of PVD), malignancies, in-
toxications, thrombosis, heart valve
diseases, suicide, trauma, others, and
undetermined. Follow-up started from
the date at dialysis initiation and ended
either at the time of death or 1 November
2016.
Era Analysis
We analyzed the mortality rate in four
eras, deﬁned by major changes in the
immunosuppression regimen in Finland:
before 1990 (before the widespread
use of cyclosporin A), between 1990
and 1999 (cyclosporine A, azathioprine,
and corticosteroids), from 2000 to 2005
(replacement of azathioprine with my-
cophenolate mofetil), and from 2006
onward (increased use of tacrolimus in-
stead of cyclosporine A and induction
therapy).
Statistical Analysis
Results are expressed as the median and
interquartile range (IQR) for continuous
variables or frequencies for categorical
variables. Comparison between groups
was performed by either ANOVA or t
test, as needed. Panel-reactive antibod-
ies were subdivided with a cutoff of 20%
(low vs. intermediate/high sensitization).
In a similar fashion, HLA-AB mismatches
were categorized with a cutoff of 2,
HLA-DR mismatches with a cutoff of 1,
and total HLAmismatches with a cutoff of
3. Categorical variables were compared
with x2 test, and we adjusted the P values
with the Bonferroni method. Patient
survival was considered the outcome
variable in Kaplan-Meier analyses, and
log-rank test was used for group com-
parison. Patient survival was compared
by their median survival time, with 95%
CIs compared in the KT, KT-D, and D
groups. Absolute risk of death was com-
pared at the 5-year and 15-year points
after start of dialysis. Hazard ratios (HRs)
with 95% CIs for 5-year mortality sec-
ondary to ischemic heart disease were
provided by Cox regression analysis and
adjusted for all of the variables available
from the three groups: age at initiation of
RRT, type of RRT, and year at initiation of
RRT and sex. Standardized mortality ra-
tios (SMRs) were calculated as the ratio
between the number of observed deaths
and number of expected deaths derived
from rates in the Finnish background
populationdrawn fromStatistics Finland.
SMRs were calculated for the entire co-
hort and separately for sex, treatment
modality, and time period. All P values
were two-tailed, and signiﬁcance was set
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ata level of 0.05. Statistical analyseswere
performed with SPSS software (version
19; SPSS Inc., Chicago, IL) and SAS version
9.4 (SAS Institute, Cary, NC). This study
was approved by the Ethical Committee
of Helsinki University Hospital.
RESULTS
Study Population
Out of 2,543 patients with T1D who
developed ESRD and initiated dialysis,
1,283 kidneys were transplanted to
1,192 patients as of 31 October 2016 af-
ter a variable time on dialysis before
transplantation. The ﬁrst patient with
T1D received a KT in August 1976.
There were no cases of patients dying
on the transplant waiting list, and there
were no preemptive transplantations.
After ﬁrst transplant failure, only 59
patients (25%) were retransplanted. In
March 2010, the national pancreas trans-
plantation program started in Finland,
and as of 1 November 2016, 78 patients
received a pancreas along with kidney
transplant. After excluding retransplanta-
tion cases and pancreas-transplanted
patients, a total of 2,383 patients re-
mained and were included in this study.
All patients were Caucasians. Follow-up
data were missing from 68 patients (no
known address in Finland). The accessi-
bility of KT has changed across time: 40%
of all patients with T1D who developed
ESRD before 1990 were transplanted.
The accessibility increased between
1990 and 1999 to 51% and between
2000 and 2005 to 53%. We observed a
decline in the accessibility of KT occur-
ring in the last 10 years (43%).
Compared with patients who experi-
enced kidney allograft loss, KT patients
with a functioning allograft were less
sensitized and had less acute rejections.
However, the KT patients with a func-
tioning allograft had more HLA-AB and
total mismatches, were older at trans-
plantation, and more often had delayed
graft function. The D patients were older
at initiation of RRT (i.e., dialysis) than the
KT-D (median 45.7 [IQR 16.9] vs. 35.6
[11.6] years; P , 0.001) and KT patients
(45.7 [16.9] vs. 41.2 [13.3] years; P ,
0.001). Also, the KT patients were older
than KT-D patients (41.2 [13.3] vs. 35.6
[11.6] years; P , 0.001). Demographic
data are detailed in Table 1.
Patient survival was compared among
the D, KT-D, and KT subgroups from the
date of initiation of dialysis therapy. The
results are shown in Fig. 1. At the end of
the second year of follow-up, 631 D pa-
tients had already died. By preserving
KT function, patients’ survival was longer
(median survival time 15.5 years [95% CI
14.4–16.6]) compared with those who
remained on dialysis (median survival
time 2.4 years [2.2–2.5]) (Fig. 2). The
most substantial difference between the
absolute risk of deathwas during the ﬁrst
years from the start of dialysis. There-
fore, the 5-year risk of death in the KT
patients was 11.5% (95% CI 9.5–13.4),
whereas it was 77.9% in the D patients
(77.3–78.4).
Even when graft function was lost,
KT-D patients lived longer (median sur-
vival time 10.7 years [95% CI 9.8–11.7])
than D patients, and the 5-year risk
of death was 20.2% (95% CI 16.0–24.2).
The corresponding risks of death within
15 years were 49.2 (47.0–51.4), 67.1
(64.9–69.1), and 96.5 (96.5–96.6) in the
KT, KT-D, and D patients, respectively.
Overall, SMRs in D patients were 48.1
(95% CI 45.2–51.1), in KT-D 21.2 (18.3–
24.5), and in KT 7.8 (7.1–8.7). The com-
bination of sex and type of treatment
showed that women in the D group had a
110.2-fold (95%CI 99.2–122.1) increased
risk of premature death compared with
the women in the background popula-
tion, whereas in men, the risk was in-
creased36.9-fold (95%CI34.2–39.8). The
corresponding ﬁgures for women in the
KT-Dgroupwere 45.5 (95%CI, 35.4–57.7)
and in the KT group 13.2 (10.9–15.9). In
men, SMRswere 16.5 (13.8–19.7) in KT-D
and 6.6 (5.8–7.5) in KT patients.
Time Trends in Mortality
The number of cases in each time period
were as follows: before 1990, 593
(24.9%); between 1990 and 1999, 664
(27.9%); between 2000 and 2005, 441
(18.5%); and from 2006 onwards, 685
(28.7%). We observed that SMRs de-
creased in all treatment modalities
Table 1—Demographic data
D (N = 1,273) KT-D (N = 237) KT (N = 873) P
Patient sex, male/female, n (%) 828 (65)/445 (35) 150 (65)/87 (35) 571 (63)/302 (37) 0.832
Age at RRT, years, median (IQR) 45.7 (16.9) 35.6 (11.6) 41.2 (13.3) ,0.001
Age at KT, years, median (IQR) d 37.4 (12.1) 43.6 (14.3) 0.011
Months on dialysis before KT, median (IQR) d 15.8 (20.0) 15.4 (20.9) 0.160
Donor sex, male/female, n (%) d 142 (60)/95 (40) 495 (57)/378 (43) 0.020
Donor age, years, median (IQR) d 44.0 (23.0) 47.0 (20.0) 0.548
DD/LD, n (%) d 232 (98)/5 (2) 835 (96)/38 (4) 0.110
HLA-AB MM #2 vs. .2, % d 97.9 vs. 2.1 88.6 vs. 11.4 0.001
HLA-DR MM #1 vs. 2, % d 94.0 vs. 6.0 90.9 vs. 9.1 0.082
Total HLA MM #3 vs. .3, % d 96.6 vs. 3.4 88.3 vs. 11.7 ,0.001
Maximum PRA I, low sensitization, % d 38.8 67.8 ,0.001
Maximum PRA II, low sensitization, % d 22.2 50.0 0.038
Occurrence of DGF, % d 20.3 27.8 0.020
Acute rejection episodes, % d 28.3 15.9 ,0.001
Patient survival, years, median (95% CI) 2.2 (2.0–2.3) 10.6 (9.6–11.7) 15.7 (14.5–16.8) ,0.001
Age at death, years, median (IQR) 49.5 (18.4) 48.3 (15.0) 52.3 (13.6) ,0.001
Low sensitization means panel-reactive antibodies ,20%. DD, deceased donor; DGF, delayed graft function; LD, living donor; MM, mismatch; PRA,
panel-reactive antibody.
care.diabetesjournals.org Ortiz and Associates 57
over time. For the D patients, there was
a 55% reduction in the SMRs from the ﬁrst
(before 1990) to the last period (2006
onward). Similarly, the corresponding
decrease in the KT-D and KT patients
was 58% between the ﬁrst and last time
periods. Detailed results are displayed in
Fig. 2. Noteworthy is that in the most
recent era, the KT SMRs were 88% lower
than SMRs in the D group, and even
when graft function was lost, the SMR
was 65% lower.
Causes of Death
We retrieved death certiﬁcates from
1,659 patients, of whom the cause of
death was undetermined in 133 (8%).
Across time and ESRD treatment mo-
dality, ischemic heart disease was the
leading cause of death. The differen-
ces between the most common causes
of death are depicted in Table 2. A com-
plete enumeration of all causes of death
according to treatment modality and
time period is exposed in Supplemen-
tary Table 1.
We observed that deaths secondary
to ischemic heart disease before 1990
reached 43% (249 out of 578 deaths).
Between 1990 and 1999, between 2000
and 2005, and after 2006, the frequen-
cies of ischemic heart disease deaths
among all recorded deaths were 45%,
48%, and 46%, respectively. To allow
comparison between groups with differ-
ent duration of follow-up, we calculated
the 5-year mortality rates secondary to
ischemic heart disease as well as the
HRs. The explanatory variables included
in themodel were age at dialysis, sex, era
of treatment, and modality of type of
kidney replacement treatment. The only
signiﬁcant variable in the model was the
modality of RRT: a functioning KT de-
creased the risk of premature cardiovas-
cular mortality at 5 years from dialysis
start by 87% (HR 0.129 [95% CI 0.009–
0.183]; P , 0.001), and, even in those
who returned to dialysis, the risk of
premature mortality was reduced by
84% (HR 0.161 [95% CI 0.102–0.252];
P , 0.001). The detailed results of the
Cox regression analysis are available in
Supplementary Table 2.
CONCLUSIONS
In the current study, we show sustained
improvement during the last 40 years in
the survival of patients with T1D in Fin-
land who developed ESRD and were
on RRT. The conspicuous progress in
diabetes care, drug therapies, dialysis
techniques, surgical procedures, and sur-
veillance of patients with KTs is the likely
explanation for the lowered risk of pre-
mature mortality in this cohort. It is of
note that the decrease in mortality was
independent of RRT modality. Similar
results were observed in Finnish patients
with T1D with ESRD compared with
patients with ESRD with glomerulo-
nephritis, but that particular investigation
Figure 1—Kaplan-Meier survival estimates after start of dialysis for patients on dialysis without
a kidney graft (D), those with failed kidney grafts (KT-D), and those with functioning kidney grafts
(KT). Median survival times shown as gray dashed lines.
Figure 2—Time trends in SMRs stratiﬁed by treatment modalities: D (dialysis), KT-D (dialysis
following failure of kidney graft), and KT (functioning kidney graft).
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was focused on the survival of patients
starting RRT at different time periods
and not on the effect of kidney allograft
loss on survival (16). Moreover, a simi-
lar reduction in mortality rates has
been observed in Swedish patients
with T1D, although that study did not
focus on patients with ESRD (17). Of note,
we show in this study that the survival
of a patient with T1D after transplanta-
tion improved up to the year 2000,
thereafter reaching a plateau. The lack
of long-term improvement in KT survival
in the last two decades has been well
described before, irrespective of the kid-
ney disease etiology (18). In our study,
we observed a conspicuous improvement
in the survival of patients with T1D who
developed ESRD and received a KT in
Finland between 1990 and 1999, after
which further improvement has been
more modest. This observation is in line
with previous studies (19).
Several studies have suggested that
intensive glycemic control may lower
the risk of long-term complications,
such as ESRD. Thus, the Diabetes Control
and Complications Trial (DCCT) showed a
reduction in the requirement of kidney
replacement therapy when diabetes was
treated intensively (20). Along with a re-
duction in the overall mortality in individ-
uals with T1D, a reduction in the mortality
of patients with ESRD has also been re-
ported (2,16). Our ﬁndings are in line with
those observed in other cohorts, but it is
of note that our study was also able to
discriminate the magnitude of improve-
ment among different RRT modalities.
It is well known that mortality in-
creases proportionally with the decrease
in kidney function. Thus, in patients with
ESRD, the treatment of choice is organ
transplantation. Particularly, patients with
T1D who develop ESRD are at high risk
of premature death due to cardiovascular
disease if they remain on dialysis treatment
(21,22). However, not all patients with
ESRDare candidates for KT, and the reason
is usually that they may be too frail with
too many comorbidities. We observed
that D patients were older at initiation of
RRT. We hypothesized that this group
could have beenmore frail, with a longer
duration of diabetes and its complica-
tions. Unfortunately, we do not have
data on comorbidities before initiation
of RRT to allow a comparison between
groups. Thus, the comparison between
the D and KT populations is hampered by
selection bias. This is particularly true for
the candidates for combined pancreas
and KT, which is usually offered to youn-
ger and healthier recipients (23). The
combined pancreas-KT program started
in Finland only after 2010. The inclusion
criteria for this program were particularly
strict at the beginning, such as age under
55 years and absence of cardiovascular
disease. As of 30 November 2016, com-
bined pancreas-KT only accounted for
78 cases. For these reasons, we excluded
such cases from this investigation. The
selection bias impacts the conclusions
one can draw from this study, as we
cannot prove causality or consider other
confounding factors affecting the candi-
dacy for transplantation.Nevertheless,we
compared KT patients who maintained
allograft function until death versus
those who lost their grafts. We observed
that patient survival was 13 years
longer than for D patients and ;5 years
longer compared with those in the KT-D
group. Thus, preserved KT function after
ﬁrst transplantation was associated with
improved patient survival. Protective fac-
tors were low titers of panel-reactive
antibodies and less acute rejection epi-
sodes. Although we do not have kidney
graft biopsies conﬁrming the cause of
graft loss, we hypothesize that immuno-
logical injury has been an important
factor for graft loss.WorseHLAmatching,
delayed graft function, and age did not
seem to affect KT survival in this pop-
ulation. Shortening time on dialysis
might effectively lower the risk of pre-
mature mortality, as previously dem-
onstrated in a cohort of Korean patients
with either T1D or type 2 diabetes (24).
Both preemptive KT and living organ
donation are rising as important practices,
as has already been stated (23). Unfor-
tunately, many of these patients, and
their relatives, might not have been
properly informed about the beneﬁt
of preemptive transplantation and are
ultimately being transplanted after the
initiation of dialysis (25). By the time
our study population developed ESRD,
preemptive transplantation was not in
practice in Finland, and this policy
changed by 2015. Even living donation
has been underused, constituting only
2 to 3% of all kidney transplants. For this
reason, we could not study the impact
of preemptive transplantation or living
donation in our population. Noteworthy
is that the retransplantation rate was
low. Possible reasons for the low odds
of being retransplanted were increased
comorbidity and longer waiting time
for a second KT due to sensitization. In
this cohort, there were no cases of
patients dying while on the transplant
waiting list, probably because of the
relatively short waiting time for a KT
in Finland (15.6 months in this co-
hort). However, it is possible that some
patients were removed from the
waiting list if a severe complication
that changed the candidacy for trans-
plantation occurred.
We observed that the SMRs decreased
in all patients with T1D with ESRD over
time, but even those who maintained
the kidney allograft function had a fourfold
increased risk of premature death com-
pared with the background population.
Nevertheless, the KT group had an SMR
65% lower than KT-D and 88% lower than
D. Of note, the highest SMRs were seen
in women on dialysis, probably because
of the low risk of mortality of this age-
group in the background population.
The second aim of this study was to
evaluate the causes of death over the
Table 2—Main causes of death in relation to the kidney replacement treatment type
Cause of death D KT KT-D Total P
Infection* 195 (18.2) 52 (13.7)† 50 (25.1)† 297 (17.9) 0.003
Malignancy* 18 (1.6)† 23 (6.1)† 2 (1.0)† 43 (2.6) ,0.001
IHD* 480 (44.4) 178 (47.1) 87 (43.7) 745 (44.9) 0.633
Stroke* 123 (11.4)† 62 (16.4)† 32 (16.1)† 217 (13.1) 0.017
PVD* 48 (4.5)† 7 (1.8)† 5 (2.5) 60 (3.6) 0.048
Total main causes‡ 864 (79.8) 322 (85.1) 176 (88.4) 1,362 (82.0)
Total number of deaths§ 1,082 (84.9) 378 (43.3) 199 (83.9) 1,659 (69.6)
Number of patients at risk 1,273 873 237 2,383
IHD, ischemic heart disease. *Number of cases (percentage of the total number of deaths).
†Statistically signiﬁcant. ‡Sumofmain causes of death (percentage of the total number of deaths).
§Total number of deaths (percentage of patients at risk).
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past 40 years. Our results conﬁrm those
previously published in which cardiovas-
cular disease was the leading cause of
death in patients with ESRD (26,27). We
observed that it remained at the top over
the 40-year period. Noteworthy is that
before transplantation, all patients are
routinely screened for malignancies, in-
fections, and cardiovascular disease. Al-
though all transplant candidates with
diabetes are screened for coronary artery
disease with a variety of tests, the Amer-
ican Journal of Cardiology clearly stated
that routine cardiac screening of asymp-
tomatic transplant candidates has not
been shown to decrease mortality (28).
This issue has been conﬁrmed in two
large randomized trials, Detection of
Ischemia in Asymptomatic Diabetics
(DIAD)andFactor64, focusedonpatients
with type 2 diabetes (29,30). No studies
similar to these have been performed in
patients with T1D. In our study, we also
observed a higher frequency of ischemic
heartdisease in transplant recipients, but
the fatal event occurred earlier in the
patients on dialysis. Of note, death in all
groups occurred at a premature age. This
fact raises doubts about the efﬁcacy of
cardiovascular screening prior to trans-
plantation. Fatal stroke events in our
study were lower than rates that the
Diabetes Epidemiology Research Interna-
tional (DERI) group observed in Japa-
nese patients with T1D receiving dialysis
(11.4% vs. 38.9%) (31). Unfortunately,
we could not retrieve data from all of
the patients concerning the use of sta-
tins, aspirin, or renin-angiotensin system
blockers. This limits the possibility of
analyzing the impact of these confound-
ers on the risk of death.
Infection-related mortality was more
prevalent inD than inKTpatients, despite
the use of immunosuppression. The risk
was especially high in patients in the
KT-D group, probably due to the additive
effect of uremic toxins and immunosup-
pression on leukocyte function. Our re-
sults are in line with a recent report from
the European registries (11). The higher
cardiovascular mortality in this popula-
tion might explain the lower risk of dying
secondary to a malignancy, as it is a
competing factor. Of note, acute com-
plications such as alcohol-related events
or violence as cause of death have not
been as prevalent in our investigation as
has been reported in patients with T1D
without ESRD (32).
The main strength of this study is the
data sources, including all patients with
T1D who received a KT from the begin-
ning of the transplant activities in Fin-
land, and we missed follow-up data
from only 2.7% of them. In addition,
we reviewed 1,659 death certiﬁcates,
and in only 8%, was the cause of death
undetermined. This provides a compre-
hensive and accurate picture of
the comorbidities that affect patient
survival.
To conclude, over the years, overall
mortality has decreased in patients with
ESRD on RRT. However, mortality due to
cardiovascular complications remains
high, and patients die young. Infectious
deaths were more common in D pa-
tients than in KT patients despite the
use of immunosuppression. Efforts
should be set on maintaining kidney
function after transplantation, as it
decreases mortality.
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